← All themes Genomics & Gene Editing

Gene Therapy

Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.

131 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Novartis NVS $279B	1,604	+89	+6%	$22B
2	2 Charles River Laboratories CRL $14.4B	560	-23	-4%	$9.86B
3	3 CRISPR Therapeutics CRSP $4.86B	492	+12	+3%	$3.67B
4	4 BridgeBio Pharma BBIO $12.7B	462	+27	+6%	$14.4B
5	5 Krystal Biotech KRYS $9.79B	368	+34	+10%	$7.32B
6	6 PTC Therapeutics PTCT $4.98B	352	-1	-0.3%	$6.51B
7	7 Sarepta Therapeutics SRPT $1.78B	345	-2	-0.6%	$2.24B
8	8 Intellia Therapeutics NTLA $1.6B	304	+11	+4%	$1.41B
9	9 Ultragenyx Pharmaceutical RARE $1.47B	298	+10	+3%	$2.05B
10	10 Vericel Corp VCEL $2.06B	280	+6	+2%	$1.78B
11	11 DELISTED Arcellx ACLX	240	+22	+10%	$6.52B
12	12 uniQure QURE $1.45B	214	-12	-5%	$972M
13	13 Allogene Therapeutics ALLO $449M	209	+37	+22%	$445M
14	14 Precigen PGEN $2.64B	206	+27	+15%	$517M
15	15 Sana Biotechnology SANA $698M	203	0	0%	$473M
16	16 Rocket Pharmaceuticals RCKT $243M	199	+13	+7%	$348M
17	17 Prime Medicine PRME $568M	192	+9	+5%	$343M
18	18 Taysha Gene Therapies TSHA $1.14B	191	-4	-2%	$1.21B
19	19 Legend Biotech LEGN $3.7B	190	-10	-5%	$1.74B
20	20 DELISTED BioLife Solutions BLFS	187	0	0%	$952M
21	21 Regenxbio RGNX $454M	178	+4	+2%	$355M
22	22 Capricor Therapeutics CAPR $383M	177	+45	+34%	$1.03B
23	23 Fate Therapeutics FATE $232M	158	+12	+8%	$88.9M
24	24 4D Molecular Therapeutics FDMT $674M	153	0	0%	$471M
25	25 Solid Biosciences SLDB $585M	150	+20	+15%	$717M